As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).
Mayank Markande takes a walk down the memory lane to relive the special debut in IPL 2018 that changed his life and set the tone for his career. The post My first IPL Match: A midnight call, Rohit’s ‘bindaas’ advice and THAT Dhoni wicket — Mayank Markande rel…
Find Strong Stocks During the Coronavirus with New Analyst Coverage
Those following along with Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will no doubt be intrigued by the recent...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Is (AGLE) Outperforming Other Medical Stocks This Year?
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial Application (CTA) by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for ACN00177, a novel engineered human enzyme therapy designed to treat Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine levels, leading to a wide range of life-altering complications and reduced life expectancy. There are currently limited treatment options for Homocystinuria.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. …
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced a new 56 week analysis on Arginase 1 Deficiency (ARG1-D) patients who have been treated with pegzilarginase from the Company’s completed Phase 1/2 clinical trial and the ongoing Phase 2 open-label extension study. The data were shared yesterday in a virtual, late-breaking oral presentation at the 6th Congress of the European Academy of Neurology.
Aeglea (AGLE) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
If you own shares in Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) then it's worth thinking about how it contributes to...
AUSTIN, Texas, April 30, 2020 -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as.
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will present a new 56 week analysis on patients who have been treated with pegzilarginase from the completed Phase 1/2 clinical trial and the ongoing Phase 2 open-label extension study in a late-breaking oral presentation at the 6th Congress of the European Academy of Neurology being held virtually May 23-26, 2020. Pegzilarginase is an enhanced human arginase that enzymatically lowers levels of the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D), a rare debilitating disease presenting in childhood with persistent hyperargininemia, severe progressive neurological abnormalities and early mortality.
Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward.
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced a proposed underwritten public offering in which it intends to offer and sell $100 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. Aeglea expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount equal to up to 15% of the securities offered in the public offering. All of the securities are being offered by Aeglea.
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underwritten public offering of 11,652,830 shares of its common stock at a price to the public of $4.75 per share. In addition, and in lieu of common stock, Aeglea is offering to certain investors pre-funded warrants to purchase up to an aggregate of 13,610,328 shares of common stock at a purchase price of $4.7499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. Aeglea has also granted the underwriters a 30-day option to purchase up to an additional 3,789,473 shares of common stock in connection with the public offering.
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Bollywood celebrates Eid with warm wishes and beautiful pictures.
AUSTIN, Texas (AP) — Aeglea Biotherapeutics Inc. (AGLE) on Thursday reported a loss of $18.7 million in its first quarter.
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter of 2021.
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...
AUSTIN, Texas, Jan. 13, 2020 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as.